We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Control-IQ Technology for High Insulin Users With Type 1 Diabetes (Higher-IQ)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05422053
Recruitment Status : Recruiting
First Posted : June 16, 2022
Last Update Posted : August 30, 2022
Sponsor:
Information provided by (Responsible Party):
Tandem Diabetes Care, Inc.

Brief Summary:
A prospective, single-arm study of 13 weeks of home use of the t:slim X2 insulin pump with Control-IQ technology in individuals with type 1 diabetes who will plan to use at least one basal rate > 3 units/hr.

Condition or disease Intervention/treatment Phase
Type 1 Diabetes Device: t:slim X2 insulin pump with Control-IQ technology 1.5 Not Applicable

Detailed Description:
The objectives of the study are to assess safety and explore glycemic outcomes with use of an automated insulin dosing (AID) system (t:slim X2 insulin pump with Control-IQ technology v1.5) in adults with type 1 diabetes who will plan to use at least one basal rate > 3 units/hr. Up to 60 participants may be recruited.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Control-IQ Technology for High Insulin Users With Type 1 Diabetes (Higher-IQ)
Actual Study Start Date : June 29, 2022
Estimated Primary Completion Date : December 30, 2022
Estimated Study Completion Date : February 15, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Diabetes Type 1

Arm Intervention/treatment
Experimental: t:slim X2 insulin pump with Control-IQ technology
Adults with type 1 diabetes will use the t:slim X2 insulin pump with Control-IQ technology 1.5 for 3-months of outpatient use. Meal and exercise challenges will be performed.
Device: t:slim X2 insulin pump with Control-IQ technology 1.5
t:slim X2 insulin pump with Control-IQ technology 1.5, and wearing the Dexcom G6 CGM.




Primary Outcome Measures :
  1. Severe Hypoglycemic Events [ Time Frame: 3 months ]
    Severe hypoglycemia (with cognitive impairment such that assistance of another individual is needed for treatment) during study compared with data on severe hypoglycemic events reported by T1D Exchange clinic registry over a 3-month time period

  2. Diabetic ketoacidosis [ Time Frame: 3 months ]
    DKA event rate

  3. Adverse device effects [ Time Frame: 3 months ]
    Number of unanticipated adverse device effects

  4. Other serious adverse events [ Time Frame: 3 months ]
    Number of other serious adverse events


Secondary Outcome Measures :
  1. Adverse events [ Time Frame: 3 months ]
    Number of Adverse events

  2. Glucose < 54 mg/dL [ Time Frame: 3 months ]
    Percent time CGM glucose < 54 mg/dL

  3. Glucose < 70 mg/dL [ Time Frame: 3 months ]
    Percent time CGM glucose < 70 mg/dL


Other Outcome Measures:
  1. Glucose time in range 70-180 mg/dL [ Time Frame: 3 months ]
    Percent time CGM glucose in range 70-180 mg/dl

  2. Glucose > 180 mg/dL [ Time Frame: 3 months ]
    Percent time CGM glucose > 180 mg/dL

  3. Glucose > 250 mg/dL [ Time Frame: 3 months ]
    Percent time CGM glucose > 250 mg/dL

  4. Glucose time in range 70-140 mg/dL [ Time Frame: 3 months ]
    Percent time CGM glucose in range 70-140 mg/dl

  5. CGM mean glucose [ Time Frame: 3 months ]
    CGM-measured mean glucose (mg/dL)

  6. Coefficient of Variation [ Time Frame: 3 months ]
    CGM measured glucose variability measured with the coefficient of variation (mg/dL)

  7. Standard Deviation [ Time Frame: 3 months ]
    CGM measured glucose variability measured with the standard deviation (mg/dL)

  8. Hemoglobin A1c [ Time Frame: 3 months ]
    Change in Hemoglobin A1c from baseline

  9. CGM Metrics by Time of Day [ Time Frame: 3 months ]
    All CGM metrics listed above (percent time) for: All 24 hours of the day, Daytime only (06:00AM to 00:00AM), Nighttime only (00:00AM to 06:00AM)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age ≥ 18 years
  • Diagnosis of type 1 diabetes for at least 1 year
  • Currently using an insulin pump (of any brand) for at least 3 months, and will plan to use at least one basal rate above 3 units/hr with the study pump
  • HbA1c < 10.5%
  • Weight ≤ 200 kg
  • Residing full-time in the United States, with no anticipated travel outside the United States during the period of study participation.
  • Participant has agreed to participate in the study; and has read, understood and signed the informed consent form (ICF); and has agreed to follow all study procedures, including suspending use of any personal CGM for the duration of the clinical trial once the study CGM is in use.
  • Willing to use only aspart (novolog) or lispro (humalog) insulin with the study pump, with no use of concentrated insulin above U-100, long-acting basal insulin injections, or inhaled insulin with the study pump.
  • Have current glucagon product to treat severe hypoglycemia (injectable or nasal) at home (will provide prescription if they do not have one)
  • Willing and able to perform the study exercise and meal challenges.
  • Have a care partner, trained in hypoglycemia and hyperglycemia treatment guidelines, present during the challenges and until the next day.
  • Investigator has confidence that the participant can successfully operate all study devices and is capable of adhering to the protocol, including ability to respond to alerts and alarms, and to provide basic diabetes self-management.

Exclusion Criteria:

  • More than 1 episode of diabetic ketoacidosis (DKA) in the past 6 months
  • More than 1 episode of severe hypoglycemia (needing assistance) in the past 6 months
  • Inpatient psychiatric treatment in the past 6 months
  • History of drug abuse (defined as any illicit drug use) or history of alcohol abuse prior to screening or unwillingness to agree to abstain from illicit drugs throughout the study.
  • For Female: Currently pregnant or planning to become pregnant during the time period of study participation
  • Use of sulfonylureas, meglitinides or other medications specifically listed in protocol or determined by investigator to interfere with the study
  • Unstable dose of SGLT-2 inhibitor, GLP-1 receptor agonist, or DPP-4 inhibitor as listed in the protocol, or starting a new non-insulin glucose lowering or weight loss agent during the trial
  • Hemophilia or any other bleeding disorder
  • History of heart, liver, lung or kidney disease determined by investigator to interfere with the study
  • History of allergic reaction to Humalog or Novolog
  • Use of glucocorticoids or other medications determined by investigator to interfere with study
  • Abnormal screening electrocardiogram consistent with increased risk during study exercise activities, such as arrhythmia, ischemia, or prolonged QTc interval. Investigator will review all electrocardiograms
  • Significant chronic kidney disease (which could impact CGM accuracy in investigator's judgment) or hemodialysis
  • History of adrenal insufficiency
  • History of abnormal TSH consistent with hypothyroidism or hyperthyroidism that is not appropriately treated
  • History of gastroparesis
  • A condition, which in the opinion of the investigator or designee, would put the participant or study at risk
  • Participation in another pharmaceutical or device trial at the time of enrollment or anticipated for during the time period of study participation
  • Employed by, or having immediate family members employed by Tandem Diabetes Care, Inc., or having a direct supervisor at place of employment who is also directly involved in conducting the clinical trial (as a study investigator, coordinator, etc.); or having a first-degree relative who is directly involved in conducting the clinical trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05422053


Locations
Layout table for location information
United States, Colorado
Barbara Davis Center Recruiting
Aurora, Colorado, United States, 80045
Contact: Darya Wodetzki    303-724-1868    DARYA.WODETZKI@CUANSCHUTZ.EDU   
Principal Investigator: Halis K Akturk, MD         
United States, Idaho
Rocky Mountain Diabetes Center Recruiting
Idaho Falls, Idaho, United States, 83404
Contact: Joann Malone    208-528-9650    joann@idahomed.com   
Principal Investigator: David Liljenquist, MD         
United States, Minnesota
International Diabetes Center Recruiting
Minneapolis, Minnesota, United States, 55416
Contact: Stephanie Zimmerman, RD,LD, CDCES    952-993-2048    Stephanie.zimmerman@parknicollet.com   
Principal Investigator: Anders L Carlson, MD         
United States, Utah
Diabetes & Endocrine Treatment Specialists Recruiting
Sandy, Utah, United States, 84093
Contact: Leslie Iverson    801-816-1010    leslie@detsutah.com   
Principal Investigator: Amnom Schlegel, MD         
Sponsors and Collaborators
Tandem Diabetes Care, Inc.
Investigators
Layout table for investigator information
Study Director: Jordan Pinsker, MD Tandem Diabetes Care
Layout table for additonal information
Responsible Party: Tandem Diabetes Care, Inc.
ClinicalTrials.gov Identifier: NCT05422053    
Other Study ID Numbers: TP-0009856
First Posted: June 16, 2022    Key Record Dates
Last Update Posted: August 30, 2022
Last Verified: August 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases
Insulin
Hypoglycemic Agents
Physiological Effects of Drugs